Dare Bioscience, Inc.

DARE • Biotechnology

$0.72

▲ +0.01 (+1.11%)

Precio actual

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$10.47M

Crecimiento

-35.4%

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 14 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:36 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.72

Change1.11%

Shares Out14.52M

Market Cap$10.47M

Enterprise Value$-1.28M

52W Range1.27 - 9.19

Beta0.97

P/E-0.87

P/S9.05

P/B14.26

P/FCF-1.03

EV/Sales-1.11

Price$0.72

Change1.11%

Shares Out14.52M

Market Cap$10.47M

Enterprise Value$-1.28M

52W Range1.27 - 9.19

Beta0.97

P/E-0.87

P/S9.05

P/B14.26

P/FCF-1.03

EV/Sales-1.11

EV/EBITDA0.13

EV/FCF0.13

Earnings Yield-114.80%

FCF Yield-97.07%

Dividend Yield0.00%

Gross Margin-137.55%

Oper. Margin-13.16%

Profit Margin-13.01%

Debt/Eq0.93

Current Ratio1.14

Quick Ratio1.14

Revenue 5Y-35.39%

Target$12.00

Target Upside1564.36%

Target Median$12.00

Target Range12.00 - 12.00

Volume65.25K

Avg Volume636.96K

EPS Surprise0.13

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

55/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

20/100

Por qué este puntaje▼

Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

DARE

Analyst sentiment

Based on 6 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-06-24

Bajo

$12.00

Promedio

$12.00

Mediana

$12.00

Alto

$12.00

Resumen de la compañía

IPO: 4/10/2014

Industria: Biotechnology

P/B i: 14.26

Deuda / Patrimonio i: 0.93

Margen operativo: -1315.51%

Margen neto: -1300.66%

ROE i: -

ROIC: -

Salud financiera

Puntaje11 / 20

Deuda / Patrimonio: 0.93

Ratio corriente: 1.14

Ratio rápido: 1.14

Estado: Moderate

Transacciones internas

Actividad reciente de ejecutivos e insiders

Grossman Jessica D.

Transacción: 06/11/2026

COMPRA

Cambio

+10,000

Precio

$2.03

Presentación

06/11/2026

Tipo

COMPRA

Matz Gregory W

Transacción: 06/11/2026

COMPRA

Cambio

+10,000

Precio

$2.03

Presentación

06/11/2026

Tipo

COMPRA

Steele Robin Joan

Transacción: 06/11/2026

COMPRA

Cambio

+10,000

Precio

$2.03

Presentación

06/11/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Grossman Jessica D.	COMPRA	+10,000	$2.03	06/11/2026	06/11/2026
Matz Gregory W	COMPRA	+10,000	$2.03	06/11/2026	06/11/2026
Steele Robin Joan	COMPRA	+10,000	$2.03	06/11/2026	06/11/2026
Kelley Susan L.	COMPRA	+10,000	$2.03	06/11/2026	06/11/2026
RASTETTER WILLIAM H	COMPRA	+10,000	$2.03	06/11/2026	06/11/2026
JOHNSON SABRINA MARTUCCI	COMPRA	+10,800	$2.50	02/18/2026	02/20/2026
JOHNSON SABRINA MARTUCCI	COMPRA	+21,600	$4.00	02/18/2026	02/20/2026
Haring-Layton MarDee	COMPRA	+49,000	$1.81	01/30/2026	02/02/2026
JOHNSON SABRINA MARTUCCI	COMPRA	+172,000	$1.81	01/30/2026	02/02/2026
Haring-Layton MarDee	COMPRA	+57,000	$2.13	09/04/2025	09/04/2025
Kelley Susan L.	COMPRA	+4,500	$2.44	07/09/2025	07/10/2025
Grossman Jessica D.	COMPRA	+4,500	$2.44	07/09/2025	07/10/2025
Matz Gregory W	COMPRA	+4,500	$2.44	07/09/2025	07/10/2025
Steele Robin Joan	COMPRA	+4,500	$2.44	07/09/2025	07/10/2025
RASTETTER WILLIAM H	COMPRA	+4,500	$2.44	07/09/2025	07/10/2025
JOHNSON SABRINA MARTUCCI	COMPRA	+107,000	$3.27	01/28/2025	01/31/2025
Haring-Layton MarDee	COMPRA	+38,000	$3.27	01/28/2025	01/31/2025
Matz Gregory W	COMPRA	+40,000	$0.43	06/05/2024	06/07/2024
Kelley Susan L.	COMPRA	+40,000	$0.43	06/05/2024	06/07/2024
RASTETTER WILLIAM H	COMPRA	+40,000	$0.43	06/05/2024	06/07/2024

Sobre la compañía

Dare Bioscience, Inc.

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

Fuente - Link

Competidores

ADTX AIMD ANL ASBP ATHA CTXR FBLG HOTH LPTX PALI

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million

GlobeNewsWire

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

Video webcast now available here

GlobeNewsWire

Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript

Seeking Alpha

Daré Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society

Daré's proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure Company continues activities necessary to advance its Sildenafil Cream toward the FDA's 505(b)(2) regulatory pathway* while in parallel launching DARE to PLAY™ Sildenafil Cream, the 503B compounded version of its proprietary sildenafil cream formulation**

GlobeNewsWire

Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value over the next 12–18 months Access the segment here

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-14	-0.33	-0.2	0.13
2026-03-26	-0.24	-0.02	0.22
2025-11-13	-0.33	-0.28	0.05
2025-08-14	-0.55	-0.45	0.1
2025-05-13	-0.63	-0.5	0.13
2025-03-31	-0.66	-0.64	0.02
2024-11-14	-0.6	-0.55	0.05
2024-08-12	-0.57	1.52	2.09
2024-05-14	-0.72	-0.84	-0.12
2024-03-28	-1.08	-0.72	0.36
2023-11-09	-1.2	-1.08	0.12
2023-08-10	-1.2	-1.2	0